← Back to headlines
Zymeworks Acquires Theravance Biopharma in $929M Deal
Zymeworks has announced its acquisition of Theravance Biopharma for $17 per share, totaling a $929 million deal, leading to a downgrade for Theravance.
29 Jun, 18:36 — 29 Jun, 18:36
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Filipino Nonprofit Receives Grant for Children's Heart Disease Program
just now
Latvian Business News: Infrastructure Funding and Slower Economic Growth
just now
NAFDAC warns Nigerians about banned energy drinks seized in Ghana
just now